A carregar...
Belatacept Resistant Rejection is Associated with CD28(+) Memory CD8 T cells
Recently newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent is associated with superior patient survival and graft function than traditional therapy but its adoption as a m...
Na minha lista:
| Publicado no: | Am J Transplant |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573634/ https://ncbi.nlm.nih.gov/pubmed/28502128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14349 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|